Company / Accounts Receivable
Amphstar Pharmaceuticals, Inc. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$143.6M
FY2025
5-year range
$78.8M / $143.6M
FY2021-FY2025
Trend
+5.3%
vs FY2024
Sector context
#40 of 113
Health Care
What the data says
At $144M, Amphstar Pharmaceuticals, Inc.'s accounts receivable ranks #40 of 113 in the Health Care sector. Accounts Receivable has increased for 6 consecutive years, from $45M in FY2019 to $144M in FY2025.
Based on SEC 10-K filings.
$144M in FY2025 with a 5-year CAGR of +16.8%.
Improved from $115M to $144M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +17.4%
- 5-Year CAGR
- +16.8%
- 10-Year CAGR
- -
Sector benchmark
#40 of 113 in Health CareTop 35% of 113This company $143.6M Sector average $1.1B
▼
-87.4% below sector average
Key checks
Key Insights
- Amphstar Pharmaceuticals, Inc.'s accounts receivable has grown for 6 consecutive years.
- 5-year CAGR of +16.8%, indicating consistent growth.
- In FY2025, accounts receivable increased 5.3% year-over-year.
- Ranks #40 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 21.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $143.6M | +5.3% |
| FY2024 | $136.3M | +18.6% |
| FY2023 | $114.9M | +29.4% |
| FY2022 | $88.8M | +12.7% |
| FY2021 | $78.8M | +19.4% |
| FY2020 | $66.0M | +45.5% |
| FY2019 | $45.4M | -13.0% |
| FY2018 | $52.2M | +44.9% |
| FY2017 | $36.0M | +34.4% |
| FY2016 | $26.8M | -19.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026